A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

Abstract

Background

Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were shown to have ERBB2 mutations in the kinase domain. In our study, we sought to determine if similar respective gain-of-function EGFR and ERBB2 mutations were present in hepatoma and/or biliary cancers.

Methods

We extracted genomic DNA from 40 hepatoma (18) and biliary cancers (22) samples, and 44 adenocarcinomas of the lung, this latter as a positive control for mutation detection. We subjected those samples to PCR-based semi-automated double stranded nucleotide sequencing targeting exons 18–21 of EGFR and ERBB2. All samples were tested against matched normal DNA.

Results

We found 11% of hepatoma, but no biliary cancers, harbored a novel ERBB2 H878Y mutation in the activating domain.

Conclusion

These newly described mutations may play a role in predicting response to EGFR-targeted therapy in hepatoma and their role should be explored in prospective studies.

Background

Mutations in the protein-kinase enzyme family, such as the epidermal growth factor receptor (EGFR, ERBB2), found in human cancers are being investigated as promising targets for the development of novel antitumor therapies.EGFR is the first described member of a family of related transmembrane receptor tyrosine kinases. It is comprised of the following four related receptors: EGFR itself (ERBB1 or HER1), ERBB2 (HER2/neu), ERBB3 (HER3) and ERBB4 (HER4). ERBB receptors are composed of an extracellular ligand-binding domain, a transmembrane segment, and an intracellular protein tyrosine kinase domain. These receptors trigger downstream signaling pathways that are complex and multilayered. Deregulation of those ERBB receptors can lead to malignant transformation. These receptors form either homo- or heterodimeric complexes which provides amplification and diversification [1]. Heterodimerization of the ERBB2 and EGFR is associated with a more robust signaling than homodimerization [2]. Several studies showed that gain-of-function somatic mutations affecting the catalytic domain (specifically the ATP binding site, exons 18–21) of EGFR in non-small cell lung carcinomas were strongly associated with response to gefitinib and erlotinib, both related EGFR-tyrosine kinase inhibitors (TKI) [3–5]. More recently, a number of studies reported the presence of ERBB2 mutations located in the kinase domain (exons 19 and 20) in non-small cell lung carcinomas (NSCLC) that could potentially result in the activation of the tyrosine kinase activity of the receptor protein [6–9]. In addition to NSCLC, mutations in the ERBB2 kinase domain were described in gastric, colorectal, and breast cancers [10, 11]. In our study, we sought to determine if similar respective gain-of-function EGFR and ERBB2 mutations were present in hepatoma and biliary cancers to determine the potential for ERBB -targeted therapy.

Hepatoma is the most common malignant tumor of the liver with a clear rising incidence in the number of cases in the United States, and is largely attributed to the increase in hepatitis C related liver disease [12]. Cancers of the biliary tract are the second most common primary hepatobiliary cancer [13]. There is no satisfactory treatment available for patients with hepatobiliary cancers and chemotherapy has been extremely disappointing.

The poor prognosis of patients with hepatoma and biliary cancers in addition to the lack of satisfactory therapy for advanced cases indicates a need for more effective therapeutic options. EGFR signaling is implicated in both hepatic and biliary carcinogenesis. Studies indicate that EGFR is expressed in up to 85% and 80% of hepatoma and biliary cancers, respectively [14], and EGF might be required for the growth of those cells [15, 16]. ERBB2 is also expressed in a significant number of hepatoma and biliary cancers acting as an independent prognostic factor and a major contributor to carcinogenesis [17–21]. Recently, a multi-center phase 2 study looked at the efficacy and tolerability of erlotinib in advanced hepatoma and biliary cancers with encouraging results [22, 23]. In hepatoma, the reported PFS at 6 months of 32% with disease control (PR + SD) of 59% for a median duration of 4 months. The median overall survival (OS) was 13 months. In biliary cancers, the reported PFS at 6 months was 25% with disease control (PR + SD) of 55% for a median duration of 5.4 months. The median OS was 9 months.

Methods

In our study, we extracted genomic DNA from 40 hepatoma (18) and biliary cancers (22) samples, and 44 adenocarcinoma of the lung, the latter as a positive control for mutation detection. All hepatobiliary samples were paraffin-embedded while all lung samples were frozen. Hepatoma and biliary cancers were subjected to laser capture microdissection as previously described (Kurose K et al. Hum Mol Genet 2001) to enrich the neoplastic component. We subjected those samples to PCR-based semi-automated double stranded nucleotide sequencing, per routine of the Eng lab [24, 25]. Exons 18–21 (exon-intron junctions and flanking intronic regions) of EGFR were amplified using the primers and conditions described by Lynch et al [3] and those of ERBB2 were amplified using the primers and conditions described by Stephens et al [6]. Double stranded sequencing was performed with the ABI-3700. Mutations or variants were confirmed in both directions as well as confirmed by a second independent PCR reaction. All samples were tested against matched germline DNA derived from the related normal organ. Our samples were acquired on anonymised archived materials without personal identifiers, on an exempt protocol approved by the Ohio State University Institutional Review Board.

Results

All hepatoma and biliary cancers samples were negative for gain-of-function somatic mutations affecting the catalytic domain of the EGFR gene. Power calculations suggest that our negative results predict that no more than 3% of hepatoma or biliary cancers would eventually be found to carry such mutations. As a positive control for mutation detection, we sequenced EGFR exons 18–21 in 44 adenocarcinoma of the lung and found 2 (5%) with somatic delE746-A750 mutations, previously reported to be associated with gefitinib responsiveness. In contrast, 2 (11%) of the 18 hepatoma had a single novel somatic H878Y (CAT to TAT; c.2632C > T) mutation in exon 21 of ERBB2 (figure 1), while none of the biliary cancers were found to have somatic mutations. None of the matched normal tissue was found to have somatic mutations for EGFR or ERBB2 found in the tumors. These are different from the reported mutations in non-small cell lung carcinomas. The H878Y missense mutation occurring in the activation domain of ERBB2 alters a basic hydrophilic residue to an acidic hydrophilic residue, and so is predicted to affect function.

Figure 1

Somatic missense mutation, H878Y, found in genomic DNA from hepatoma (top chromatogram) but not in corresponding normal tissue (bottom panel).

Discussions and Conclusion

The lack of effective treatment for hepatobiliary tumors indicates a need for more effective therapeutic options. Emerging targeted therapies including EGFR inhibitors are offering promise in a variety of malignancies including hepatobiliary tumors. From this study, we conclude that gain-of-function somatic mutations affecting the catalytic domain of EGFR as described in non-small cell lung carcinomas have a predicted low yield in hepatoma and biliary cancers. A recently published study showed the lack of somatic mutations in EGFR tyrosine kinase domain in 100 hepatocellular carcinomas confirming our findings [26]. In contrast, we showed that 11% of hepatocellular carcinomas tested have an ERBB2 mutation occurring in the activation domain. None were found in biliary cancer specimens. Given the availability of agents interfering with ERBB2 signaling and the established role of ERBB2 in the EGFR signaling pathway, we speculate that these newly described mutations may play a role in predicting response to EGFR-targeted therapy in hepatoma in predicting response to agents that target ERBB2 and/or EGFR in hepatoma. Interestingly, one such agent, lapatinib (a dual EGFR/ERBB2 TKI), was recently reported to have activity in hepatomas (TGCR = 40%) but not in biliary cancers (TGCR = 26%) [27]. Cohen et al showed that in head and neck cancers although responses to gefitinib or erlotinib were not linked to kinase mutations of EGFR, one single response case was actually linked to a mutation in exon 20 of ERBB2 establishing the potential predictive value of such mutations on responses to agents that target ERBB2 and/or EGFR [28]. In conclusion, our findings suggest that mutations in the tyrosine kinase domain of ERBB2 in hepatoma may underlie responsiveness to agents that target ERBB2 and/or EGFR. This should trigger similar analysis as part of correlative studies in prospective studies.